Share
370 Posts.
lightbulb Created with Sketch. 16
clock Created with Sketch.
08/09/18
15:50
Share
Originally posted by ahjay
↑
No disrespect to anyone but I'm not sure going down memory lane is relevant to current
Immutep direction......CVAC in no uncertain terms showed promise and results but
the cold hard facts are it was too involved to interest modern pharma, borne out by
primas inability to offload to anyone but someone who has been unable to interest
anyone in making an offer...
Let's arrive at the here and now, Prima of 2014 upon the acquisition of ImmutepSA
and the abandonment of CVAC managed to convince Ridgeback to invest $15M
and to this day they still hold....
I note.....Edisons valued IMM at 17c recently, adjusted down to 12c if Ridgeback's
options, notes, warrants are exercised.....
As macca says, AIPAC is the key, basically in about 9 months we'll know if it is
good,half good or no good.....There lies the success or failure of immutep IMO....
Shares on issue have increased but in that regard targeted market value has
increased far more.....
We are mixed up in the high end of the I/O landscape and in an advantageous
position at this point in time in regard to potential, interest from others is strong
and backed up by a strong management, if "efti" comes good for us the shares
on issue will be inconseqentional IMO.....The biotech community understands
the share register will rise until income can be produced, it's the way of funding
without selling the farm off in bits and pieces.....
The future is looking bright, the past doesn't matter...
Expand
No disrespect to you either, ahjay, but the 'trip down memory lane' as you put it had nothing to do with what happened with CVAC. The underlying message there was all views on a forum like this should be welcomed, whether negative or positive as in some of those 'negative' responses such as boiler used to make there were some important points to learn from. Personal attacks on a poster for 'going against the herd' should not be tolerated.